the product in the database has an inactive status
indications:
Treatment of symptoms associated with seasonal or perennial allergic rhinitis (nasal congestion, sneezing, leaky aqueous discharge, nasal and conjunctiva pruritus).
Composition:
1 tabl sustained release contains 5 mg of Cetirizine dihydrochloride and 120 mg of pseudoephedrine hydrochloride.
Action:
The combination of antihistamine and sympathomimetic. Cetirizine is a selective H receptor antagonist1. Quickly and almost completely absorbed from the gastrointestinal tract. Plasma proteins are 93% bound. It is not extensively metabolised during the first pass through the liver. It is excreted in the urine, mainly unchanged (65%). T0,5 is 9 h. Pseudoephedrine is a sympathomimetic medicine, showing mainly α-mimetic activity. Narrows blood vessels, which leads to the reduction of nasal congestion. It is quickly and completely absorbed from the gastrointestinal tract. When given in prolonged release form, it reaches maximum plasma concentration within 8 hours. It is metabolized in the liver at about 25-50% and excreted unchanged in the urine and as a metabolite.
Contraindications:
Hypersensitivity to any component of the drug, ephedrine or piperazine derivatives. Do not use in patients with hypertension, ischemic heart disease, severe renal insufficiency, untreated hyperthyroidism, severe arrhythmia, increased intraocular pressure or urinary retention. Do not administer during the treatment with MAO inhibitors and within 14 days after its completion or during the use of antihypertensive drugs (such as β-blockers), sympathomimetics, dihydroergotamine or amphetamine derivatives. Do not use in children under 12 years.
Precautions:
Do not use in patients with galactose intolerance, Lapp lactase deficiency or malabsorption of glucose-galactose. Carefully use in patients over 50 years of age with diabetes, hyperthyroidism, tachycardia, arrhythmia, angina pectoris, moderate renal or hepatic failure, prostatic hyperplasia, ureteral dysfunction, previous stroke or an increased risk of its occurrence, as well as after alcohol consumption. Exercise caution in patients taking digitalis glycosides, tricyclic antidepressants, linezolid, guanethidine, reserpine, phenothiazine derivatives, sedatives.
Pregnancy and lactation:
Do not use during pregnancy and breast-feeding.
Side effects:
Tachycardia, dry mouth, nausea, weakness, pain and dizziness, drowsiness or insomnia, nervousness were often observed. uncommon - agitation and anxiety. Rarely are vomiting, arrhythmia, hypersensitivity reactions, convulsions, tremors, hallucinations, urination disorders, dry skin, rash, increased sweating, urticaria, pallor, hypertension, increased liver enzymes and bilirubin in the blood. Very rarely, there may be disturbances of taste, angioneurotic edema, drug-induced rash, circulatory collapse.
Dosage:
Adults and children over 12 years orally 1 tablet 2 times a day (morning and evening). Patients with moderate renal or hepatic insufficiency receive 1 tablet. per day. Warning. Tablets should not be divided, chewed or chewed. Do not use for more than 2-3 weeks; after resolution of acute symptoms, treatment can be continued with antihistamines without the addition of pseudoephedrine.
(C)
